Skip to main content

Lloyd George W.'s Form 4 filing

Royalty Pharma plc (RPRX) · filed Dec 5, 2025

Accession no.
0001814899-25-000008
Filed
Dec 5, 2025
Trade date
Dec 3, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 1 non-derivative transaction. Open-market sales total $4.37M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lloyd George W.CIK 0001814899Officer (EVP, Investments & CLO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 3, 2025Class A Ordinary SharesSSaleDisposed−110,000$39.77F2−$4,374,700110,000Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.36 to $40.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

In addition to the holdings of Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares. The Reporting Person also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting conditions and may, upon vesting, be converted into an equivalent number of Class A Ordinary Shares.

Read the full filing on SEC EDGAR (opens in a new tab)